THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock […]
Category Archives: Pr Newswire
Pr Newswire
Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026
07
Feb
Feb
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product details, refund policies, and what consumers commonly research before purchasing an at-home teeth whitening kit New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Oral and dental […]
TOKYO, Feb. 7, 2026 /PRNewswire/ — SIG Service INC. (Headquarters: Chiyoda-ku, Tokyo), the operator of Doorzo, closed 2025 with record-breaking results, driven by its unwavering global vision of becoming “your gateway to Japan.” Over the course of the year, Doorzo further solidified its position as a leading cross-border shopping platform by broadening its international presence, […]
SINGAPORE, Feb. 7, 2026 /PRNewswire/ — AWE Asia 2026 concluded this week at Singapore Expo, convening the global extended reality (XR) and artificial intelligence (AI) community for three days of keynotes, developer sessions, track discussions, and hands-on demos. Across the program, a clear theme emerged: as AI moves beyond screens and into real-world environments, XR […]
Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion Therapies Data Presented at International Stroke Conference Data Show That LT3001 Delivers Meaningful Functional Improvements in Patients Suffering from Disabling Acute Ischemic Stroke (AIS) TAIPEI, Feb. 7, 2026 /PRNewswire/ — Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase […]
Converging AI, autonomy, and secure communications push MUM-T from experimentation to scalable deployment LONDON, Feb. 7, 2026 /PRNewswire/ — According to a new Frost & Sullivan analysis, Human-Machine Integration/Manned–Unmanned Teaming (MUM-T), Global, 2025–2027, the rapid convergence of artificial intelligence, autonomy, and secure networked communications is transforming modern military doctrine and accelerating the shift toward multi-domain […]
Research Introduces 577 Epigenetic Mechanism for Asian Skin SHANGHAI, Feb. 7, 2026 /PRNewswire/ — The IMCAS World Congress 2026, an internationally recognized forum for aesthetic medicine and clinical research, opened on January 31 in Paris. As a global platform supporting collaboration in dermatology, plastic surgery, and aging science, IMCAS facilitates the exchange of interdisciplinary research and clinical […]
Pr Newswire
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
06
Feb
Feb
PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease Topline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) — Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients […]
Pr Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
06
Feb
Feb
IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026 IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease […]
Pr Newswire
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
06
Feb
Feb
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001) All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-A On the Investigator’s Global Assessment (IGA), 69% […]